ADMA Biologics (NASDAQ:ADMA) Upgraded to Strong-Buy at Canaccord Genuity Group

ADMA Biologics (NASDAQ:ADMA) was upgraded by research analysts at Canaccord Genuity Group to a “strong-buy” rating in a research note issued on Monday,Zacks.com reports.

A number of other equities research analysts have also recently commented on ADMA. Zacks Research raised shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 2nd. Cantor Fitzgerald reissued a “neutral” rating on shares of ADMA Biologics in a research report on Thursday, March 26th. Wall Street Zen cut shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Saturday. Mizuho decreased their price target on shares of ADMA Biologics from $30.00 to $24.00 and set an “outperform” rating for the company in a report on Monday, April 13th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a report on Tuesday, December 23rd. Three equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $25.67.

ADMA Biologics Price Performance

NASDAQ ADMA opened at $10.78 on Monday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.74 and a current ratio of 6.71. The firm’s 50 day moving average price is $13.23 and its 200-day moving average price is $15.76. ADMA Biologics has a 52-week low of $7.21 and a 52-week high of $25.67. The company has a market cap of $2.57 billion, a PE ratio of 17.97 and a beta of 0.82.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.20. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. The firm had revenue of $139.16 million for the quarter, compared to the consensus estimate of $139.80 million. During the same period last year, the firm earned $0.46 earnings per share. The company’s quarterly revenue was up 18.4% on a year-over-year basis. Sell-side analysts forecast that ADMA Biologics will post 0.93 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Steve Elms purchased 7,000 shares of the firm’s stock in a transaction on Thursday, March 5th. The stock was acquired at an average price of $15.67 per share, with a total value of $109,690.00. Following the completion of the acquisition, the director owned 2,038,730 shares in the company, valued at approximately $31,946,899.10. This represents a 0.34% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the firm’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $15.63, for a total transaction of $157,800.48. Following the completion of the transaction, the chief operating officer directly owned 466,600 shares of the company’s stock, valued at approximately $7,292,958. This represents a 2.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 3.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Salomon & Ludwin LLC acquired a new stake in shares of ADMA Biologics in the third quarter worth $25,000. Rothschild Investment LLC increased its stake in shares of ADMA Biologics by 373.8% in the third quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 1,495 shares during the period. Summit Securities Group LLC acquired a new stake in shares of ADMA Biologics in the fourth quarter worth $29,000. Clearstead Advisors LLC increased its stake in shares of ADMA Biologics by 55.7% in the third quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 795 shares during the period. Finally, iSAM Funds UK Ltd acquired a new stake in shares of ADMA Biologics in the third quarter worth $34,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.